Nymox Reports Completion of Large New 2 Year Follow-up Study of NX-1207 for BPH

16-Nov-2007

Nymox Pharmaceutical Corporation announced completion of a large new 2 year follow-up study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of over one hundred subjects involved in the Company's Phase 2 U.S. clinical trial initiated in 2005. Individuals in the study were assessed 2 years after NX-1207 treatment for symptomatic improvement, treatment outcomes, and durability of efficacy. This is the largest cohort of patients treated with NX-1207 followed for as long as 2 years thus far. The Company expects to report the results of the follow-up study in the next 2 weeks once final analysis of the data is completed.

NX-1207 has successfully completed three U.S. trials and several smaller long term follow-up studies to date. The company's Phase 2 double-blind, placebo controlled, randomized study showed positive efficacy and safety results for NX-1207 after 3 months in patients with BPH. Overall, patients treated with NX-1207 showed after 3 months a mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement compares favorably to the 3.5 to 5 points reported in published studies of currently approved drugs for BPH and reached statistical significance when compared to placebo. Subjects treated with NX-1207 also showed an overall significant reduction in mean prostate volume. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. Subjects treated with NX-1207 had no serious side effects. In particular, patients given NX-1207 had no (0%) significant sexual side effects.

https://www.bionity.com/en/news/74336/nymox-reports-completion-of-large-new-2-year-follow-up-study-of-nx-1207-for-bph.html